Moreover, proprotein convertase subtilisin/Kexin type 9 (PCSK9) inhibitors can reduce LDL-C by inhibiting the degradation of low density lipoprotein receptor (Ldlr), while PCSK9 gain-of-function mutation promotes AAA occurrence in mice (106). The gene discussed is LDLR; the disease is triple-A syndrome.